The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy
Open accessAbstract
BACKGROUND: Immunoglobulin A nephropathy (IgAN) is the most common cause of chronic renal failure among primary glomerulonephritis patients. The best treatment for IgAN remains poorly defined. We planned a long-term, prospective, open-label, multicentre, centrally randomized controlled trial to assess whether the combination of prednisone and ramipril was more effective than ramipril alone in patients with proteinuric IgAN. METHODS: Ninety-seven biopsy-proven IgAN patients with moderate histologic lesions, 24-h proteinuria > or =1.0 g and estimated glomerular filtration rate (eGFR) > or = 50 ml/min/ 1.73 m(2) were randomly allocated to receive a 6-month course of oral prednisone plus ramipril (combination therapy group) or ramipril alone (monotherapy group) for the total duration of follow-up. The primary outcome was the progression of renal disease defined as the combination of doubling of baseline serum creatinine or end-stage kidney disease (ESKD). The secondary outcomes were the rate of renal function decline defined as the eGFR slope over time, and the reduction of 24-h proteinuria. RESULTS: After a follow-up of up to 96 months, 13/49 (26.5%) patients in the monotherapy group reached the primary outcome compared with 2/48 (4.2%) in the combination therapy group. The Kaplan-Meier analysis showed a significantly higher probability of not reaching the combined outcome in the combination therapy group than in the monotherapy group (85.2% versus 52.1%; log-rank test P = 0.003). In the multivariate analysis, baseline serum creatinine and 24-h proteinuria were independent predictors of the risk of primary outcome; treatment with prednisone plus ramipril significantly reduced the risk of renal disease progression (hazard ratio 0.13; 95% confidence interval 0.03-0.61; P = 0.01). The mean rate of eGFR decline was higher in the monotherapy group than in the combination therapy group (-6.17 +/- 13.3 versus -0.56 +/- 7.62 ml/min/ 1.73 m(2)/year; P = 0.013). Moreover, the combined treatment reduced 24-h proteinuria more than ramipril alone during the first 2 years. CONCLUSIONS: Our results suggest that the combination of corticosteroids and ramipril may provide additional benefits compared with ramipril alone in preventing the progression of renal disease in proteinuric IgAN patients in the long-term follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Nakao, N., Yoshimura, A., Morita, H., Takada, M., Kayano, T., & Ideura, T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12229-5 · Cited by 970
RetractedLevey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Kunz, R., Friedrich, C., Wolbers, M., & Mann, J. F. E. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-1-200801010-00190 · Cited by 717
Ruggenenti, P., Perna, A., Gherardi, G., Gaspari, F., Benini, R., & Remuzzi, G. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04433-x · Cited by 574
Corticosteroids in IgA nephropathy: a randomised controlled trial
Pozzi, C., Bolasco, P., Fogazzi, G., Andrulli, S., Altieri, P., Ponticelli, C., & Locatelli, F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03563-6 · Cited by 532
Corticosteroid Effectiveness in IgA Nephropathy: Long-Term Results of a Randomized, Controlled Trial
Pozzi, C., Andrulli, S., Del Vecchio, L., Melis, P., Fogazzi, G. B., Altieri, P., Ponticelli, C., & Locatelli, F. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000103869.08096.4f · Cited by 484
Treatment of IgA Nephropathy with ACE Inhibitors: A Randomized and Controlled Trial
Praga, M., Gutiérrez, E., González, E., Morales, E., & Hernández, E. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000068460.37369.dc · Cited by 345
Alamartine, E., Sabatier, J.-C., Guerin, C., Berliet, J.-M., & Berthoux, F. (1991) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(12)80284-8 · Cited by 283
Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy
Russo, D., Minutolo, R., Pisani, A., Esposito, R., Signoriello, G., Andreucci, M., & Balletta, M. M. (2001) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2001.25176 · Cited by 247
Schena, F. P. (1997) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/12.3.418 · Cited by 242
Self-citationLv, J., Zhang, H., Chen, Y., Li, G., Jiang, L., Singh, A. K., & Wang, H. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.07.029 · Cited by 238
Manno, C., Strippoli, G. F. M., D’Altri, C., Torres, D., Rossini, M., & Schena, F. P. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.03.013 · Cited by 169
Self-citationCorticosteroid therapy in IgA nephropathy with nephrotic syndrome: a long-term controlled trial.
Lai, K. N., Lai, F. M., HO, C. P., & Chan, K. W. (1986) · PubMed · Cited by 167
Steroid Therapy during the Early Stage of Progressive IgA Nephropathy
Kobayashi, Y., Hiki, Y., Kokubo, T., Horii, A., & Tateno, S. (2008) · The Nephron journals/Nephron journals · doi:10.1159/000188848 · Cited by 148
Katafuchi, R., Ikeda, K., Mizumasa, T., Tanaka, H., Ando, T., Yanase, T., Masutani, K., Kubo, M., & Fujimi, S. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00194-x · Cited by 142
Johnston, P. A., BROWN, J., Braumholtz, D. A., & DAVISION, A. (1992) · QJM · doi:10.1093/oxfordjournals.qjmed.a068700 · Cited by 131
Maschio, G., Cagnoli, L., Claroni, F., Fusaroli, M., Rugiu, C., Sanna, G. M., Sasdelli, M., Zuccalà, A., & Zucchelli, P. C. (1994) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/9.3.265 · Cited by 119
ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis
Woo, K. T., Lau, Y., Wong, K.-S., & Chiang, G. S. C. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00432.x · Cited by 109
Shoji, T., Nakanishi, I., Suzuki, A., Hayashi, T., Togawa, M., Okada, N., Imai, E., Hori, M., & Tsubakihara, Y. (2000) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(00)70326-x · Cited by 107
ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy
Remuzzi, A., Perico, N., Sangalli, F., Vendramin, G., Moriggi, M., Ruggenenti, P. L., & Remuzzi, G. (1999) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1999.276.3.f457 · Cited by 104
Julian, B. A., & Barker, C. (1993) · PubMed · Cited by 51
Alternate-Day Prednisone Therapy in IgA Nephropathy
Julian, B. A., & Barker, C. V. (2015) · Contributions to nephrology · doi:10.1159/000422413 · Cited by 47
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Intensive supportive care plus immunosuppression in IgA nephropathy
Rauen, T., Eitner, F., Fitzner, C., Sommerer, C., Zeier, M., Otte, B., Panzer, U., Peters, H., Benck, U., Mertens, P. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1415463 · Cited by 726
Rodrigues, J. C., Haas, M., & Reich, H. N. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07420716 · Cited by 555
Lv, J., Zhang, H., Wong, M. G., Jardine, M. J., Hladunewich, M., Jha, V., Monaghan, H., Zhao, M., Barbour, S., Reich, H., et al. (2017) · JAMA · doi:10.1001/jama.2017.9362 · Cited by 540
Coppo, R., on behalf of the VALIGA study of the ERA-EDTA Immunonephrology Working Group, Troyanov, S., Bellur, S., Cattran, D., Cook, H. T., Feehally, J., Roberts, I. S. D., Morando, L., Camilla, R., et al. (2014) · Kidney International · doi:10.1038/ki.2014.63 · Cited by 498
Metadata
- Authors
- Manno, C., Torres, D. D., Rossini, M., Pesce, F., & Schena, F. P.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-07-23
- Volume
- 24
- Issue
- 12
- Pages
- 3694-3701
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2151689843
- Cited by
- 311
- References
- 25
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.